Close Menu

NEW YORK — Interpace Biosciences said on Monday that it has signed an agreement to sell $20 million in Series B preferred stock and that it is planning a one-for-10 reverse stock split.

According to the Parsippany, New Jersey-based company, 1315 Capital will purchase $19 million worth of the preferred stock, with the remaining $1 million being sold to existing investor Ampersand Capital Partners. The preferred stock is convertible into common stock at a conversion price of $.60 per share prior to the planned reverse stock split.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.